FGP
CLB icon

Freestone Grove Partners’s Core Laboratories CLB Stock Holding History

Freestone Grove Partners’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,406
Closed -$201K – 695
2025
Q1 		$201K Buy
13,406
+2,961
+28% +$49.6K ﹤0.01% 539
2024
Q4 		$181K Buy
+10,445
New +$202K ﹤0.01% 540

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Freestone Grove Partners's CLB Position: Q2 2025 in Review

Freestone Grove Partners sold out of Core Laboratories (CLB) in Q2 2025, closing a stake of 13,406 shares — an estimated $201K sold.

Freestone Grove Partners first reported a position in CLB in Q4 2024 and held it in 2 quarters. The position peaked at $201K in Q1 2025. 191 funds tracked by Wall St. Rank hold CLB as of Q2 2025.

  • Freestone Grove Partners reported no remaining Core Laboratories position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 13,406 Core Laboratories shares in Q2 2025, an estimated $201K.
  • Freestone Grove Partners first reported a position in Core Laboratories in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Core Laboratories position peaked at $201K in Q1 2025.
  • 191 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.